## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($91.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma**
- Source: Business Wire | 20251217T160754 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL). This first-of-its-kind chemotherapy-free dual-targeted immunotherapy offers a new treatment option for eligible patients. The approval is based on Phase 3 inMIND trial data demonstrating significantly improved progression-free survival compared to placebo.

**2. Incyte Says European Commission Approves Minjuvi Combination Therapy for Follicular Lymphoma**
- Source: marketscreener.com | 20251217T170810 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL) who are not candidates for hematopoietic stem cell transplant. This approval marks a significant step for patients in Europe battling this type of blood cancer, offering a new treatment option. The news follows earlier reports of Incyte presenting data at ESMO Congress 2025 and obtaining FDA Breakthrough designation for other pipeline candidates.

**3. Incyte wins EU approval of Xencor-partnered lymphoma drug**
- Source: Seeking Alpha | 20251217T165416 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved a drug regimen including its Xencor-partnered antibody drug Minjuvi. This treatment, also known as tafasitamab, is approved as a late-line option for certain adult patients with follicular lymphoma, a type of blood cancer. The drug will now be available in the EU.

**4. Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma**
- Source: Yahoo Finance | 20251217T112000 | Bullish | Relevance: 100%
- Incyte announced that the European Commission has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). This approval provides a new chemotherapy-free treatment option, marking the second indication for Minjuvi and addressing a significant unmet need for patients with this incurable cancer. The decision is based on the Phase 3 inMIND trial, which showed a statistically significant improvement in progression-free survival for the combination therapy.

**5. Is Incyte’s 2025 Surge Justified by Cash Flow Outlook and Oncology Pipeline Progress?**
- Source: Simply Wall Street | 20251217T105117 | Bullish | Relevance: 100%
- Incyte's stock has seen a significant surge over the past year, up 39.8%, driven by an expanding oncology and immunology portfolio. Despite recent fluctuations, the company scores a solid 5/6 valuation score on Simply Wall St's framework, indicating it is undervalued. Both Discounted Cash Flow and Price vs. Earnings analyses suggest Incyte is significantly undervalued compared to its intrinsic value and earnings potential.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.08M) |
| Sells | 17 ($23.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $24M sold (17 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Momentum building: MRS_10 improving +3.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.12 indicates undervaluation relative to growth. Forward P/E 12.6x attractive for 13% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.1B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.12 |
| Forward P/E | 12.6 |
| Current P/E | 14.2 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -2.1% to 1.4% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. RSI neutral at 46. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.41% (CS: 57) | Neutral |
| RSI_14 | 45.7 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.253x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.31
- **Stop Loss:** $91.11 (6.4% risk)
- **Target:** $103.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $14,888.43
- **Portfolio %:** 14.89%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*